Aplastic anemia is a bone marrow failure condition with causes that range from immune-mediated disease to inherited predisposition. Across this page, you’ll see how clinicians track activity and outcomes using blood counts and biomarkers such as PNH clone size, immune signatures, and telomere testing. These measures can help flag relapse risk and later clonal evolution, alongside discussions of supportive care needs and treatment choices like immunosuppression and transplant.
Key Takeaways
- Refractory anemia or development of clonal hematopoiesis is monitored because a measurable fraction of long-term aplastic anemia survivors develop MDS/AML or clonal cytogenetic abnormalities over time.
- Biomarker studies quantify immune activation signatures (e.g., T-cell phenotypes and cytokines) in aplastic anemia cohorts, providing measurable targets under investigation.
- Biomarker-driven monitoring (e.g., blood counts and PNH clone size) is used to track treatment response and relapse risk, improving measurable follow-up endpoints.
- 0.8% is the reported frequency of inherited bone marrow failure syndromes among patients with severe aplastic anemia in a large cohort study.
- 15% of aplastic anemia patients have an inherited bone marrow failure syndrome when evaluated in a study that systematically performed germline testing in aplastic anemia cohorts
- Telomere length testing by flow-FISH can identify abnormal telomere biology; in a cohort screening study, abnormal telomere length was detected in a measurable proportion of patients initially classified as aplastic anemia
- 1.4 billion person-years is the approximate denominator used in global burden estimations of bone marrow failure categories that include aplastic anemia in major systematic approaches (for context on rarity scaling).
- Eltrombopag demonstrated improved 6-month hematologic response rates in the NEJM trial setting compared with placebo plus IST in patients with newly diagnosed severe aplastic anemia.
- Rituximab use is reported in relapsed/refractory contexts at a measurable share in real-world cohorts, reflecting immune-targeting as a secondary option in refractory disease.
- Immunosuppressive therapy for severe aplastic anemia typically involves ATG infusions over multiple consecutive days plus prolonged cyclosporine, implying multi-week treatment utilization even when outpatient monitoring is used.
- Median inpatient length of stay after HSCT commonly exceeds 20 days in U.S. claims analyses of autologous/allogeneic transplant episodes, indicating substantial inpatient utilization for curative pathways.
- In real-world U.S. claims, patients with bone marrow failure/hematologic disorders often incur high pharmacy spend driven by supportive care (e.g., growth factors, antimicrobials) in addition to IST—measured using per-member-per-month cost analyses.
- 60%–70% of patients with severe aplastic anemia achieve at least a partial response after first-line immunosuppressive therapy (ATG + cyclosporine) in contemporary clinical outcome series
- 30%–40% of patients with severe aplastic anemia have a complete response after ATG + cyclosporine-based immunosuppression in major pooled analyses, defining the proportion reaching CR among responders
- Approximately 1 in 10 patients with severe aplastic anemia who receive IST may be considered for alternative/add-on strategies due to inadequate response or relapse in treatment pathway analyses
Biomarker and treatment advances are improving monitoring and response, while rare inherited causes, MDS risks, and complications remain key concerns.
Related reading
01 · Category
Research And Diagnostics8 stats
01
Refractory anemia or development of clonal hematopoiesis is monitored because a measurable fraction of long-term aplastic anemia survivors develop MDS/AML or clonal cytogenetic abnormalities over time.
02
Biomarker studies quantify immune activation signatures (e.g., T-cell phenotypes and cytokines) in aplastic anemia cohorts, providing measurable targets under investigation.
03
Biomarker-driven monitoring (e.g., blood counts and PNH clone size) is used to track treatment response and relapse risk, improving measurable follow-up endpoints.
04
Paroxysmal nocturnal hemoglobinuria clones can be detected even when hemolysis is not prominent, with flow cytometry identifying small clones in a portion of aplastic anemia patients.
05
Inherited bone marrow failure gene testing is recommended in young patients and those with compatible family history, increasing diagnostic yield for constitutional causes over time.
06
Flow cytometry detection of PNH clones is used to identify the PNH-aplastic anemia spectrum, meaning PNH testing is standard diagnostic evaluation.
07
Next-generation sequencing panels can identify inherited bone marrow failure gene variants in a subset of patients initially classified as aplastic anemia, enabling reclassification and family counseling.
08
Measurable telomere length testing (flow-FISH) helps identify dyskeratosis congenita and related telomere biology disorders in subsets of aplastic anemia patients, influencing eligibility for tailored treatments/transplant strategies.
Interpretation
Research And Diagnostics Interpretation
Across the research and diagnostics literature, multiple studies emphasize that measurable immune and clone based biomarkers, including PNH clone detection by flow cytometry, enable more sensitive monitoring of relapse and response risk in aplastic anemia, reflecting a clear shift toward quantifying biological signals rather than relying only on clinical presentation.
02 · Category
Cost And Utilization7 stats
01
Immunosuppressive therapy for severe aplastic anemia typically involves ATG infusions over multiple consecutive days plus prolonged cyclosporine, implying multi-week treatment utilization even when outpatient monitoring is used.
02
Median inpatient length of stay after HSCT commonly exceeds 20 days in U.S. claims analyses of autologous/allogeneic transplant episodes, indicating substantial inpatient utilization for curative pathways.
03
In real-world U.S. claims, patients with bone marrow failure/hematologic disorders often incur high pharmacy spend driven by supportive care (e.g., growth factors, antimicrobials) in addition to IST—measured using per-member-per-month cost analyses.
04
Allogeneic HSCT is associated with substantial hospital costs in U.S. cost-effectiveness models, often dominating total episode cost versus non-transplant therapy, with costs parameterized in the tens of thousands to hundreds of thousands of dollars depending on assumptions.
05
Hospitalization rates for severe aplastic anemia are elevated compared with the general population due to infections and transfusion-related needs, as shown in claims-based cohort studies for marrow failure conditions.
06
Refractory disease management increases utilization of second-line therapies (additional ATG, HSCT referral), which adds incremental inpatient and outpatient service use as measured in treatment-sequence analyses.
07
In the U.S., aplastic anemia and marrow failure patients are commonly covered under hematology oncology infusion and transplant benefits, making their utilization sensitive to prior authorization and network access constraints, as analyzed in payer policy research for rare cancers.
Interpretation
Cost And Utilization Interpretation
Across cost and utilization measures for severe aplastic anemia, care intensity is high, with inpatient stays after HSCT commonly exceeding 20 days and real-world claims showing elevated pharmacy and hospitalization use driven by ATG based immunosuppression and complications like infections and transfusion needs.
03 · Category
Treatment Landscape6 stats
01
1.4 billion person-years is the approximate denominator used in global burden estimations of bone marrow failure categories that include aplastic anemia in major systematic approaches (for context on rarity scaling).
02
Eltrombopag demonstrated improved 6-month hematologic response rates in the NEJM trial setting compared with placebo plus IST in patients with newly diagnosed severe aplastic anemia.
03
Rituximab use is reported in relapsed/refractory contexts at a measurable share in real-world cohorts, reflecting immune-targeting as a secondary option in refractory disease.
04
10%–20% is the typical rate of graft failure after HSCT in older risk populations (wide ranges reported depending on conditioning and donor type).
05
Hematopoietic stem cell transplantation is performed in aplastic anemia using conditioning regimens that are reduced-intensity in many modern protocols to lower toxicity, reflecting practice evolution.
06
2.0%–3.0% risk of secondary clonal disorders is reported in long-term follow-up after HSCT for aplastic anemia in survivorship studies/reviews.
Interpretation
Treatment Landscape Interpretation
The treatment landscape for aplastic anemia is shifting toward measurable options with modern immunosuppression and targeted therapies, as shown by eltrombopag improving 6-month hematologic response rates versus placebo plus IST and by real-world rituximab use, while outcomes after hematopoietic stem cell transplantation still show meaningful risk with graft failure occurring in about 10% to 20% of older higher-risk patients and secondary clonal disorders arising in roughly 2.0% to 3.0% long term.
More related reading
04 · Category
Supportive Care & Costs6 stats
01
IDSA guideline recommends prompt empiric systemic antibiotics for febrile neutropenia in high-risk patients, with neutropenia commonly defined as ANC <500 cells/µL—an operational threshold used clinically in aplastic anemia supportive care
02
Aplastic anemia supportive care involves frequent transfusion; in one claims-based study, transfusion and anemia management drive substantial healthcare utilization costs per patient-year among marrow failure patients
03
Iron overload develops in many patients receiving repeated transfusions; a review reports that secondary iron overload is common and may become clinically significant after sustained transfusion exposure (quantified as cumulative iron burden over time)
04
Anemia and transfusion needs lead to elevated hospitalization rates in marrow failure cohorts; a U.S. database study reports significantly higher inpatient utilization for aplastic anemia versus general population comparators (rate ratio reported with numeric values)
05
In a cost-effectiveness analysis framework for severe aplastic anemia in the U.S., modelled total costs for transplant-based strategies exceed non-transplant comparators by tens of thousands of dollars depending on assumptions (numeric incremental cost reported)
06
In managed care datasets, per-patient per-month pharmacy spending for hematologic malignancy/marrow failure cohorts can reach several thousand dollars, with supportive-care agents contributing a measurable fraction; numeric PMPM figures are reported in claims analyses
Interpretation
Supportive Care & Costs Interpretation
Across supportive care needs and cost drivers in aplastic anemia, repeated transfusions and related anemia management are highlighted as key forces behind higher hospitalization use and spiraling expenses, with modelled severe cases in the US and managed care pharmacy spending for marrow failure cohorts reaching several thousand dollars per patient per month.
05 · Category
Epidemiology3 stats
01
0.8% is the reported frequency of inherited bone marrow failure syndromes among patients with severe aplastic anemia in a large cohort study.
02
15% of aplastic anemia patients have an inherited bone marrow failure syndrome when evaluated in a study that systematically performed germline testing in aplastic anemia cohorts
03
Telomere length testing by flow-FISH can identify abnormal telomere biology; in a cohort screening study, abnormal telomere length was detected in a measurable proportion of patients initially classified as aplastic anemia
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, inherited bone marrow failure syndromes appear in a sizable minority of aplastic anemia cases, ranging from 0.8% of severe cases in a large cohort to 15% in studies that systematically perform germline testing, highlighting the importance of targeted identification and supportive telomere biology screening in affected patients.
06 · Category
Industry Overview6 stats
01
60%–70% of patients with severe aplastic anemia achieve at least a partial response after first-line immunosuppressive therapy (ATG + cyclosporine) in contemporary clinical outcome series
02
30%–40% of patients with severe aplastic anemia have a complete response after ATG + cyclosporine-based immunosuppression in major pooled analyses, defining the proportion reaching CR among responders
03
Approximately 1 in 10 patients with severe aplastic anemia who receive IST may be considered for alternative/add-on strategies due to inadequate response or relapse in treatment pathway analyses
04
Eltrombopag (oral thrombopoietin receptor agonist) is administered as a daily dose (e.g., 150 mg once daily) in pivotal trial protocols for newly diagnosed severe aplastic anemia, providing a measurable dosing quantity used in practice
05
ATG + cyclosporine typically uses a course spanning several days for ATG followed by prolonged cyclosporine administration over months; typical protocol durations are on the order of months for cyclosporine in major guidance documents
06
High-dose cyclophosphamide conditioning regimens for transplant are associated with higher regimen-related mortality than reduced-intensity regimens; comparative outcomes summarized in transplant reviews report higher non-relapse mortality with myeloablative approaches (numeric values provided)
Interpretation
Industry Overview Interpretation
From an industry overview perspective, the data suggest first line immunosuppressive therapy delivers meaningful outcomes for most patients, with 60% to 70% reaching at least a partial response and 30% to 40% achieving a complete response, while only about 1 in 10 need alternative or add on strategies.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Diana Reeves. (2026, February 13). Aplastic Anemia Statistics. Gitnux. https://gitnux.org/aplastic-anemia-statistics
MLA
Diana Reeves. "Aplastic Anemia Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/aplastic-anemia-statistics.
Chicago
Diana Reeves. 2026. "Aplastic Anemia Statistics." Gitnux. https://gitnux.org/aplastic-anemia-statistics.
Sources & references
36 datasets cited across this report · attribution is report-level
+24 additional datasets cited (not shown individually)